Pfizer (PFE), Astellas Pharma Inc. Reports Amendments to Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. today announced amendments to the protocols for two registrational Phase 3 trials ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
